AiCuris raises $75M for anti-infectives pipeline

Germany's AiCuris raised close to $75 million in its second venture round, one of the biggest series the country's life sciences industry has seen in recent years. The developer has a pipeline of anti-infectives for herpes simplex virus, HIV, hepatitis B, hepatitis C, and multi-resistant bacteria. And the developer says it is actively seeking out-licensing deals for several of its programs. The company was spun out of Bayer four years ago. AiCuris release | Report

Suggested Articles

Pfizer's eczema hopeful has been building its case to challenge Sanofi and Regeneron's Dupixent, but safety issues could stand in its way.

Cedrik Britten, M.D., becomes the biotech’s new chief medical officer to help run its adoptive cell therapy and TCR bispecifics platform.

Broad Institute researchers showed that base-editing the Tmc1 gene preserved hair cells that helped transmit sound in the ears of mice.